The article reports on impact of the Trans-Pacific Partnership (TPP) on the pharmaceutical industry. Topics discussed include hike in prices of Daraprim, required for treatment of HIV patients, warnings from the nonprofit public health group MSF (Doctors Without Borders) on rise in prices of generic treatments due to TPP.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados